ChromaCode, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2025 | $4 M | No. 4 | $2 to $10 million | equity | SEC | |
| Feb 2022 | $38 M | No. 3 | $10 to $50 million | equity | SEC | |
| Aug 2019 | $39 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2017 | $12 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
ChromaCode, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2025).
SEC Form D · Feb 2025
The industry group it chose in its notices: Other Health Care.
SEC Form D · Feb 2025
That is all the official record says: ChromaCode, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
2 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | Fund or asset manager | not stated | not stated | Holds shares (fund report, Jun 2026) | SEC Form N-PORT |
| T. Rowe Price Health Sciences Portfolio | Fund or asset manager | not stated | not stated | Held shares (fund report, Mar 2026) | SEC Form N-PORT |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 17 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Paul Flook | Executive officer | Feb 2025 |
| Mark McDonough | Executive officer | Feb 2023 |
| Alexander G. Dickinson | Executive officer | Mar 2022 |
| Vikram C. Lambda | Executive officer | Mar 2022 |
| Gregory J. Gosch | Executive officer | Dec 2020 |
| Lynne C. Rollins | Executive officer | Dec 2020 |
| Lynne J. Rollins | Executive officer | Apr 2017 |
| Aditya Rajagopal | Director | Feb 2025 |
| Justin Klein | Director | Feb 2025 |
| Paul Flook | Director | Feb 2025 |
| Alexander G. Dickinson | Director | Feb 2023 |
| Carol G. Gallagher | Director | Feb 2023 |
| Jenny G. Yip | Director | Feb 2023 |
| Justin G. Klein | Director | Feb 2023 |
| Kevin G. O'Boyle | Director | Feb 2023 |
| Mark McDonough | Director | Feb 2023 |
| Pat G. Smerkers | Director | Feb 2023 |
| Aditya G. Rajagopal | Director | Mar 2022 |
| Carol C. Gallagher | Director | Mar 2022 |
| James C. Blair | Director | Mar 2022 |
| Jenny C. Yip | Director | Mar 2022 |
| Justin C. Klein | Director | Mar 2022 |
| Kevin C. O'Boyle | Director | Mar 2022 |
| Pat C. Smerkers | Director | Mar 2022 |
| Patrick C. Balthrop | Director | Mar 2022 |
| Aditya J. Rajagopal | Director | Dec 2020 |
| Gregory J. Gosch | Director | Dec 2020 |
| Christopher C. MacGriff | Director | Aug 2019 |
| Axel Justin Scherer | Director | Apr 2017 |
| Peter Justin Klein | Director | Apr 2017 |